Adamis Pharmaceuticals traded at $0.36 this Thursday July 28th, increasing $0.01 or 1.89 percent since the previous trading session. Looking back, over the last four weeks, Adamis Pharmaceuticals gained 23.82 percent. Over the last 12 months, its price fell by 65.88 percent. Looking ahead, we forecast Adamis Pharmaceuticals to be priced at 0.39 by the end of this quarter and at 0.36 in one year, according to Trading Economics global macro models projections and analysts expectations.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Peers Price Day Year
Adma Biologics 2.17 0.01 0.46% 34.78%
Adamis Pharmaceuticals 0.36 0.01 1.89% -65.88%
Brainstorm Cell Therapeutics 2.55 -0.05 -1.92% -27.56%
Cara Therapeutics 9.04 -0.10 -1.09% -25.90%
GlaxoSmithKline 1,743.00 -12.80 -0.73% 23.93%
Glaxosmithkline 42.93 -0.61 -1.40% 7.06%
Merck & Co 89.94 -1.29 -1.41% 16.91%
Pfizer 50.72 -1.23 -2.37% 18.53%
RedHill Biopharma 0.87 0.06 6.90% -86.76%

Indexes Price Day Year
USND 12163 130.17 1.08% -17.70%

Adamis Pharmaceuticals
Adamis Pharmaceuticals Corporation is a specialty biopharmaceutical company. It is focused on developing and commercializing products in therapeutic areas, including allergy, opioid overdose, respiratory and inflammatory disease. Its product includes, SYMJEP (epinephrine) Injection 0.3 miligram for treatment of acute allergic reactions, including anaphylaxis, for patients weighing 66 pounds or more, and SYMJEPI (epinephrine) Injection 0.15 miligram for the treatment of anaphylaxis for patients weighing 33-65 pounds. Its other product candidates includes ZIMHI, a high dose 5 miligram naloxone injection, based on the approved Symject injection device for the treatment of opioid overdose, and APC-400 (tempol) for the treatment of respiratory diseases including asthma, respiratory syncytial virus, influenza and COVID-19, APC-1000 a hydrofluoroalkane (HFA) inhalable oral steroid for the treatment of asthma and COPD APC-4000 Fluticasone, a dry powder inhalation for the treatment of asthma.